726 related articles for article (PubMed ID: 24226808)
1. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
[TBL] [Abstract][Full Text] [Related]
2. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
5. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
Bahit MC; Lopes RD; Wojdyla DM; Hohnloser SH; Alexander JH; Lewis BS; Aylward PE; Verheugt FW; Keltai M; Diaz R; Hanna M; Granger CB; Wallentin L
Int J Cardiol; 2013 Dec; 170(2):215-20. PubMed ID: 24192334
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
[TBL] [Abstract][Full Text] [Related]
7. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
[TBL] [Abstract][Full Text] [Related]
8. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
[TBL] [Abstract][Full Text] [Related]
10. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
11. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
14. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
15. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
16. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
[TBL] [Abstract][Full Text] [Related]
18. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC;
Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
20. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.
Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z
J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
